Comparing leg positions during radiation therapy for vulvar cancer
Impact of Treatment Positioning on Radiation Therapy RTOG Toxicity in Patients With Vulvar Cancer
This study is testing whether different leg positions during radiation therapy can affect skin side effects and treatment time for people with vulvar cancer.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 20 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | Female |
| Sponsor | King Hussein Cancer Center Academic / other |
| Drugs / interventions | radiation |
| Locations | 1 site (Amman) |
| Trial ID | NCT05014191 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of different leg positions (straight-leg vs. frog-leg) on radiation toxicity in patients with non-metastatic vulvar cancer receiving Volumetric Arc Therapy (VMAT). The research aims to assess acute skin toxicity as per RTOG guidelines and evaluate the impact of positioning on treatment time and the need for re-simulation based on Cone Beam CT deviations. By focusing on a rare cancer type, this study seeks to fill a gap in the existing literature regarding optimal radiation therapy positioning.
Who should consider this trial
Good fit: Ideal candidates are women aged 18 and older with biopsy-confirmed vulvar cancer at FIGO stages I-IVA who are receiving curative radiation treatment.
Not a fit: Patients whose radiation therapy plans do not cover inguinal lymph nodes or those who are pregnant will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved radiation therapy protocols that minimize skin toxicity for vulvar cancer patients.
How similar studies have performed: While there is limited literature specifically addressing radiation therapy positioning in vulvar cancer, similar studies in other cancer types have shown that treatment positioning can significantly affect outcomes.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 years * ECOG PS = 0-1 * Women with Bx confirmed vulvar cancer FIGO stage I-IVA (treated with curative intent) Exclusion Criteria: * Patients whom radiotherapy plans do not cover inguinal lymph nodes will be excluded. Vulnerable patients will be excluded (pregnant)
Where this trial is running
Amman
- King Hussein Cancer Center — Amman, Jordan (Recruiting)
Study contacts
- Principal investigator: Fawzi J Abuhijla — King Hussein Cancer Center
- Study coordinator: FAWZI J Abuhijla, MD, MSc
- Email: fhijle@khcc.jo
- Phone: +962796500577
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.